Thrombocytopenia Treatment Market is the condition wherein which the patient has a low platelet count. The root cause for the thrombocytopenia are the platelet splenic sequestration, inefficiency in the production of the platelets and the destruction of the platelets. Thrombocytopenia Treatment Market is either inherited or acquired. It usually occurs owing to various disorders such as leukemia and immune system related conditions. This is commonly found in both adults and children. In thrombocytopenia condition show very less symptoms and is mild. In some cases, the count of the platelets is so low that it causes dangerous internal bleeding, as the patient affected with the thrombocytopenia leads to delayed blood clotting or sometimes no blood clotting. In February 2018, Shionogi & Co., Ltd announced that the New Drug Application (NDA) for lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, has been accepted for filing and has been granted Priority Review by the U.S. Food & Drug Administration (FDA).